MercadoLibre vs Amazon: Which E-Commerce Giant Stock Has More Upside? — Neutral
AMZN MELI Zacks Investment Research — November 19, 2025MELI's margin pressure and regional volatility stack up against AMZN's steadier profit gains in the race for more upside.
TSS Q3 Earnings & Revenues Fall Y/Y Even As 2026 Outlook Improves — Positive
TSSI Zacks Investment Research — November 19, 2025TSSI shares plunge after a weak Q3 earnings, but rising AI demand, stronger operations and upbeat guidance suggest growth may accelerate in 2026.
U.S. Outperformance in Sight? ETFs to Play Morgan Stanley's Forecast — Positive
MS Zacks Investment Research — November 19, 2025Morgan Stanley sees U.S. equities outpacing global markets into 2026, with AI-driven gains and small-cap strength supporting its upbeat S&P 500 outlook.
Dolby's Q4 Earnings & Revenues Surpass Estimates, Increase Y/Y — Positive
DLB Zacks Investment Research — November 19, 2025DLB posts a solid Q4 beat as product strength and growing Dolby Atmos and Vision adoption fuel a strong fiscal finish.
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference — Neutral
INDV PRNewsWire — November 19, 2025RICHMOND, Va. , Nov. 19, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference: Piper Sandler 37th Annual Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Tuesday, December 2 nd.
CEA Industries (BNC) Launches Comprehensive Treasury Dashboard and Provides Corporate Update — Neutral
BNC GlobeNewsWire — November 19, 2025Louisville, CO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC) (“BNC” or the “Company”), which manages the world's largest corporate treasury of BNB, today announced the launch of its new Treasury Dashboard (“dashboard”), now live on CEAIndustries.com. The dashboard offers investors a consolidated and regularly updated view of certain of BNC's operating metrics, BNB holdings, treasury strategy, and capital markets activities.
Conagra Brands: Income And Stability In A Turbulent Market — Positive
CAG Seeking Alpha — November 19, 2025Conagra Brands offers a defensive investment opportunity, trading at a multi-year low valuation and a forward P/E of 10. CAG's 8% dividend yield and stable, well-known brands support its appeal despite recent revenue and EPS declines. Recent earnings beat expectations, suggesting major headwinds may already be priced in, with a 5% stock uptick post-results.
Oklo ($OKLO) | Pony.ai ($PONY) | Archer Aviation ($ACHR) | NANO Nuclear Energy ($NNE) — Positive
ACHR NNE OKLO PONY Green Stock News — November 19, 2025Welcome to the Green Stock News brief for Wednesday November 19th. Here are today's top headlines: Oklo (NYSE: OKLO) and Siemens Energy signed a binding contract for Siemens to design and deliver the power conversion system for Oklo's first Aurora advanced fission reactor.
Toyota Motor: Confirmed As A Durable Long-Term Defensive Buy After Q2 Results — Neutral
TM Seeking Alpha — November 19, 2025Toyota is transitioning from a traditional automaker into a software and services platform built on multiple strong brands. Its hybrid-focused approach protects margins and avoids risky overspending on BEVs. A more balanced global footprint and an expanding financial services arm reduce earnings volatility.
S&P500 and Nasdaq 100: Nvidia's 7% Implied Move Raises Stakes for US Stocks Today — Positive
NVDA FXEmpire — November 19, 2025Futures rise as Nvidia's high-stakes earnings test drives sentiment across tech stocks, US indices, and the broader stock market today.
IntelePeer Supercharges AI Platform with Microsoft Azure Cosmos DB for Enterprise-Grade Performance — Neutral
MSFT Business Wire — November 19, 2025DANIA BEACH, Fla.--(BUSINESS WIRE)--IntelePeer, an end-to-end conversational and agentic AI platform provider, today announced it has integrated advanced capabilities of Microsoft Azure Cosmos DB into its conversational and agentic AI platform, giving multi-location healthcare organizations and medical practices enterprise-grade performance and scalability for delivering superior patient experiences. The result of a collaborative effort by engineering teams at IntelePeer and Microsoft, the inte.
Reddit: Business Resilience Undervalued, Healthy Consolidation Creates A Buying Opportunity — Positive
RDDT Seeking Alpha — November 19, 2025Reddit proved business resilience supported by strong execution capability. Advertising revenue and ARPU are growing rapidly, with fast EBITDA margin improving toward industry-leading levels. Valuation is attractive, with a projected 30% revenue CAGR and strong capital returns justifying a premium, and a target price of $255 is set.
Can CleanSpark's Data Center Push Unlock New AI Revenue Streams? — Positive
CLSK Zacks Investment Research — November 19, 2025CLSK pivots from pure Bitcoin mining to build AI-ready data centers, aiming to unlock long-term growth through diversified digital infrastructure.
Lumen and Meter Launch AI-Driven WAN-to-LAN Solution for Enterprises — Positive
LUMN Zacks Investment Research — November 19, 2025LUMN's collaboration with Meter debuts a unified WAN-to-LAN solution built to simplify AI-ready enterprise connectivity and operations.
Is Percipio the Key to Reshaping Skillsoft's Market Positioning? — Positive
SKIL Zacks Investment Research — November 19, 2025SKIL's Percipio drives soaring AI learning adoption and major workforce wins, strengthening its position in the evolving upskilling market.
Gladstone Capital: The BDC Is Back On The Growth Track, It's A Buy — Positive
GLAD Seeking Alpha — November 19, 2025Gladstone Capital has been one of my equity-focused BDC picks, which as opposed to FDUS and TRIN has delivered unpleasant returns. Recently, GLAD announced a dividend cut, which also came as a surprise to me. Yet, the Q4 2025 data points, in my view, indicate a clear turning point.
Astrotech Announces Review of Strategic Alternatives to Maximize Shareholder Value — Neutral
ASTC GlobeNewsWire — November 19, 2025AUSTIN, Texas, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that its Board of Directors has initiated a review of strategic alternatives in order to explore ways to maximize shareholder value. The review will include a range of potential actions, including raising equity capital, reverse mergers, combination transactions, and the sale of all or part of the Company's business, and other possible strategic or financial transactions.
Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) — Neutral
LGVN GlobeNewsWire — November 19, 2025MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) to be held December 1-4, 2025 in San Diego, CA. “We are excited to have been selected to present important laromestrocel data at this leading forum for Alzheimer's research and clinical investigation,” said Joshua …
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 — Neutral
RNA PRNewsWire — November 19, 2025SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah …
Nvidia stock price forecast: NVDA is extremely cheap ahead of earnings — Positive
NVDA Invezz — November 19, 2025Nvidia stock price has pulled back in the past two weeks, moving from the year-to-date high of $212 to $180. This retreat will either accelerate or reverse once the company publishes its financial results later today.